Ulcerative colitis trials recruiting in Louisiana
All Ulcerative colitis trials nationally
15
Recruiting in Louisiana
11
Cities with sites
Cities in Louisiana
Metairie 4Shreveport 4Baton Rouge 3Lafayette 3Mandeville 3Marrero 3New Orleans 3Monroe 2New Iberia 2Houma 1West Monroe 1
Recruiting trials in Louisiana
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
- A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention